Lorus gets first patent in China

Lorus Therapeutics (TSX:LOR) received allowance of its first patent in China for novel drug candidates from its small molecule program. The Chinese patent covers composition of matter for Lorus’ lead anticancer small molecule LOR-253, as well as composition and uses of its lead antimicrobial compound LOR-220.  Lorus has similar patents pending worldwide for the two [...]

Oncolytics ready for final step with Reolysin

After a 10-year journey, Oncolytics Biotech (TSX:ONC; NASDAQ:ONCY ) is ready to take the final clinical step with its sole Reolysin drug as a treatment for a broad range of cancers. “Our product has really shown a breadth of activity in a wide variety of cancers that we had hoped it would way back when [...]

Miraculins develops new assay in preeclampsia program

Miraculins (TSX-V:MOM) has developed an ultrasensitive assay for the detection of soluble endoglin, optimized for serum and urine, in an ELISA format as part of its preeclampsia program.  Endoglin is the lead biomarker in its preeclampsia portfolio. “Our initial focus will be to offer this assay to investigators as a research-use-only kit to support preeclampsia [...]

Dundee reinstates buy on Cardiome

Reflecting new Phase 3 data from Cardiome Pharma (TSX:COM; NASDAQ:CRME) and Merck (NYSE:MRK) on Friday, Dundee Securities reinstated its “buy” rating on Cardiome, raising its 12-month price target to $10 from $8.  The stock closed at $8.24 on the TSX Friday. Analyst David Martin writes that he previously had the stock “under review,” pending the [...]

Cardiome and Merck release pivotal data for Brinavess IV

In a new Phase 3 study, Brinavess (vernakalant) intravenous, an investigational compound being developed in the European Union by Cardiome Pharma (NASDAQ: CRME; TSX: COM) and Merck (NYSE: MRK) to treat atrial fibrillation, was shown to be superior to amiodarone injection in converting patients’ heart rate from AF to sinus rhythm within 90 minutes of [...]

Medicago to begin trading on TSX tomorrow

Medicago (TSX-V:MDG) has received final approval to graduate to the TSX from the TSX Venture Exchange at the start of trading tomorrow, using the same stock symbol. The company also entered into standby equity distribution agreement to sell up to $10 million of new common shares in tranches to YA Global Master SPV, a fund managed by [...]

Lorus announces 1-for-30 share consolidation

The board of Lorus Therapeutics (TSX:LOR) has approved a one-for-30 share consolidation in accordance with the authority granted by shareholders at the company’s annual meeting last November.  The stock closed Wednesday at 9 cents. The company has set May 25 as the record date for the share roll back, with trading on a consolidation adjusted [...]

Tekmira plans NASDAQ listing

Tekmira Pharmaceuticals (TSX:TKM) plans to apply to list its common shares on the Nasdaq stock market in the next few months. “Many of our peers have securities listed in the U.S. and we believe doing so is a logical step in the evolution of Tekmira to be appropriately valued as a leader in the RNA [...]

IntelGenx buys back CPI-300 from Cary Pharma

IntelGenx (TSX-V:IGX; OTCBB:IGXT) has acquired full rights to CPI-300, a high-strength formulation of the active ingredient in the antidepressant Wellbutrin XL, from Cary Pharmaceuticals after the companies agreed to terminate their 2007 collaborative development agreement. In addition to certain potential pre-commercialization payments and in the event of CPI-300 being commercialized, IntelGenx will pay Cary 10% [...]

Amorfix and Epitomics to develop monoclonal antibodies

Amorfix Life Sciences (TSX:AMF) and Epitomics of California and China have entered into an agreement to develop high-affinity monoclonal antibodies against a number of targets for cancer. Amorfix has identified several disease specific epitopes on misfolded proteins with its ProMIS platform discovery technology, which will be used by Epitomics to generate highly specific monoclonal antibodies. [...]

« Previous Page — Next Page »